Home › Research › Drug development
Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective
Mariana Conceição, Leonardo Delello Di Filippo, Jonatas Lobato Duarte, Fernando Pereira Beserra, Maria Palmira Daflon Gremião, Marlus Chorilli. Brain, behavior, & immunity - health, 2024-10-25
Topic: Disease mechanisms in lab and animal studies
Drug repurposing, also known as drug repositioning, involves identifying new applications for drugs whose effects in a disease are already established. Doxycycline, a broad-spectrum antibiotic belonging to the tetracycline class, has demonstrated potential activity against neurodegenerative diseases like Alzheimer's and Parkinson's. However, despite its promise, the repurposed use of doxycycline encounters challenges in reaching the brain in adequate concentrations to exert its effects. To address this issue, nanostructured systems offer an innovative approach that can enhance brain targeting and the desired therapeutic outcomes. This review discusses the advances in doxycycline repurposing for Alzheimer's disease, presenting physicochemical and biological aspects that permeate doxycycline's repositioning and its application in nano-based delivery systems.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Conceição, M., Di Filippo, L. D., Duarte, J. L., Beserra, F. P., Gremião, M. P. D., & Chorilli, M. (2024). Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective. Brain, behavior, & immunity - health. https://doi.org/10.1016/j.bbih.2024.100894
Vancouver
Conceição M, Di Filippo LD, Duarte JL, Beserra FP, Gremião MPD, Chorilli M. Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective. Brain, behavior, & immunity - health. 2024. doi:10.1016/j.bbih.2024.100894. PMID: 39525305.
BibTeX
@article{conceicao2024-39525305,
author = {Conceição, Mariana and Di Filippo, Leonardo Delello and Duarte, Jonatas Lobato and Beserra, Fernando Pereira and Gremião, Maria Palmira Daflon and Chorilli, Marlus},
title = {{Repurposing doxycycline for Alzheimer's treatment: Challenges from a nano-based drug delivery perspective}},
journal = {Brain, behavior, \& immunity - health},
year = {2024},
doi = {10.1016/j.bbih.2024.100894},
pmid = {39525305},
url = {https://doi.org/10.1016/j.bbih.2024.100894}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- Doxycycline, a broad-spectrum antibiotic belonging to the tetracycline class, has demonstrated potential activity against neurodegenerative diseases like Alzheimer's and Parkinson's.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Evidence strengthLow
How this study scored 43/100
Published in a peer-reviewed journal. Scored zero for study design, sample size, effect reported, studied in people and randomised / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multi-centre collaboration and free to read, so those were left out: it earned 24 of the 56 points we could judge it on, which is 43 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Brain, behavior, & immunity - health) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 4 / 5 | 2024 — within 3 year(s) of the newest study here |
| Sample size | 0 / 4 | Participant count not stated — scores zero (not stated in the record — scored 0) |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 0 / 3 | Not stated whether this was studied in people — scores zero (not stated in the record — scored 0) |
| Randomised / blinded | 0 / 2 | No randomisation or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multi-centre collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 39525305) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 24 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 24 of the 56 points we could judge it on is 43 out of 100. |
| Total | 43 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related studies in Drug development
Also tagged “repurposing”
234 studies in the library carry the topic tag “repurposing”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 234 tagged studies.